Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:NBP

I-Mab Q3 2025 Earnings Report

I-Mab logo
$1.36 +0.02 (+1.12%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.36 0.00 (0.00%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

I-Mab EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

I-Mab Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

I-Mab Announcement Details

Quarter
Q3 2025
Date
12/18/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

I-Mab Earnings Headlines

Contrasting Valion Bio, Inc. Common Stock (NASDAQ:VBIO) & I-Mab (NASDAQ:NBP)
October 1 at 6:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073700
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357466/0/en/novabridge-appoints-martin-dewhurst-to-board-of-directors-as-an-independent-director.html
Elon will prove them wrong again
Elon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no driver in major U.S. cities. Veteran tech investor James Altucher says Musk is applying the same playbook to a new project he calls his infinite money glitch, expected to launch October 21. Altucher, who has tracked tech breakthroughs for nearly four decades, calls this the biggest one he has ever covered.tc pixel
October 4 at 1:00 AM  |  Paradigm Press (Ad)
NovaBridge Biosciences to Participate in September Investor Conferences
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3351880/0/en/novabridge-biosciences-to-participate-in-september-investor-conferences.html
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938801-novabridge-biosciences-nbp-q2-2026-earnings-call-transcript
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348212/0/en/novabridge-reports-first-half-2026-financial-results-and-highlights-pipeline-momentum-and-strategic-execution.html
See More I-Mab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like I-Mab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on I-Mab and other key companies, straight to your email.

About I-Mab

I-Mab (NASDAQ:NBP) is a biotechnology company focused on discovering, developing and commercializing innovative biologic medicines, with an emphasis on cancer and other serious diseases. The company’s research programs are primarily based on monoclonal antibodies, bispecific antibodies and other immune-based therapies designed to target tumor cells or modify the immune response.

I-Mab’s pipeline has included givastomig (also known as TJ-CD4B), a bispecific antibody designed to target Claudin 18.2 and activate 4-1BB immune signaling. The company has also developed or partnered on other investigational antibody programs, including therapies directed at CD38, CD47 and CD73. These programs have been evaluated for potential use in cancers such as gastric, gastroesophageal, pancreatic and blood cancers, although development status can vary by program and geography.

Founded in 2016, I-Mab originally operated as a China-based biopharmaceutical company and expanded its activities internationally through research, development and licensing collaborations. In recent years, the company has pursued a greater focus on global development and the United States market while restructuring or transferring certain China-related operations and assets. I-Mab has been associated with founder and Chairman Dr. Jingwu Zang and has operated research and corporate activities in both China and the United States.

View I-Mab Profile
Earnings Tools